Greggs acknowledged that the rising popularity of weight loss drugs is impacting its financial performance, as consumers shift towards healthier options and smaller portion sizes. The bakery chain's CEO, Roisin Currie, stated there was "no doubt" these appetite-suppressing drugs were influencing consumer behavior, contributing to the company's "lacklustre profits and a muted forecast for the coming year."

While Greggs did not specify the exact financial impact, Currie's comments suggest a correlation between the increasing use of GLP-1 drugs and a change in consumer demand. This shift is prompting Greggs to adapt its product offerings to cater to evolving customer preferences. The company has observed a growing demand for "protein and fibre" and generally healthier options.

The market context reveals a broader health trend influencing the food industry. Several firms have reported changes in customer appetites linked to weight loss medications. This trend is pushing companies like Greggs to innovate and offer products that align with the dietary needs of consumers using these drugs.

Greggs has historically been known for its high-fat pasties, cakes, and pastries. However, the company has been actively diversifying its menu to include healthier alternatives. In July, Greggs announced plans to target customers on weight loss drugs by introducing smaller portions and protein-rich products. This strategy included the launch of its egg-pot alongside its "eggs at Greggs" advertising campaign.

Looking ahead, Greggs aims to ensure it offers snack products that cater to customers using GLP-1 drugs. The company's ability to adapt to changing consumer preferences and successfully introduce healthier options will be crucial in mitigating the impact of weight loss drugs on its bottom line and ensuring future growth.